Topical and systemic drugs
PreclinicalSmall molecule
Topical and systemic drugs is one of 29 small molecule programs targeting Skin Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Skin Disease
#DrugCompanyPhaseTrials
1Ilumya
Sun Pharmaceutical Industries, Inc.Approved
Zyvox
PfizerApproved
Allegra
CChattem
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Cubicin
BBaxter Healthcare Corporation
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Clarinex
OOrganon and Co
Approved
Viagra
VViatris Specialty LLC
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Topical and systemic drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details